BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
CymaBay Therapeutics, Inc. (Nasdaq – CBAY)
Under the terms of the agreement, CymaBay Therapeutics will be acquired by Gilead Sciences, Inc. (Nasdaq - GILD) for $32.50 per share in cash or a total equity value of $4.3 billion. The investigation concerns whether the CymaBay Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Gilead Sciences is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/cymabay-therapeutics-inc-nasdaq-cbay/.
Masonite International Corporation (NYSE – DOOR)
Under the terms of the agreement, DOOR will be acquired by Owens Corning (NYSE – OC) for $133.00 in cash per share in a transaction valued at approximately $3.9 billion. The investigation concerns whether the DOOR Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Owens Corning is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/masonite-international-corporation-nyse-door/.
RayzeBio, Inc. (Nasdaq – RYZB)
Under the terms of the agreement, RayzeBio will be acquired by Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $4.1 billion. Under the terms of the agreement, RayzeBio stockholders will receive $62.50 per share in cash upon completion of the proposed transaction. The investigation concerns whether the RayzeBio Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/rayzebio-inc-nasdaq-ryzb.
ZeroFox Holdings, Inc. (Nasdaq – ZFOX)
Under the terms of the Merger Agreement, ZeroFox will be acquired by Haveli Investments. ZeroFox shareholders will receive $1.14 per share in an all-cash transaction with an enterprise value of approximately $350 million. The investigation concerns whether the ZeroFox Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Haveli Investments is paying fair value to shareholders of the Company.
Additional information can be found at https://www.brodskysmith.com/cases/zerofox-holdings-inc-nasdaq-zfox/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
